Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Italian Journal of Pediatrics
Published in: Italian Journal of Pediatrics 1/2017

Open Access 01-12-2017 | Letter to the Editor

Indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wGA group: is there still room for debating?

Authors: Gianvincenzo Zuccotti, Valentina Fabiano

Published in: Italian Journal of Pediatrics | Issue 1/2017

Login to get access

Abstract

Guidelines on immunoprophylaxis for prevention of RSV infection recommend it in preterm babies born before 29 wGA; in babies affected by bronchopulmonary dysplasia or congenital heart defects; and in post-heart transplantation patients. On the contrary, immunoprophylaxis is not recommended in preterm babies born between 29 and 35 wGA. We evaluated the impact of RSV-related healthcare expenditures in infants in the first 3 years of life in Italy, Lombardy Region. In light of the collected data and considering the cost of a complete palivizumab prophylaxis, extending it to babies 29–32 wGA, aged less than 6 months, appears to be a cost-effective strategy.
Literature
1.
Anderson EJ, Krilov LR, DeVincenzo JP, Checchia PA, Halasa N, Simoes EAF, et al. SENTINEL1: an observational study of respiratory syncytial virus hospitalizations among U.S. Infants born at 29 to 35 Weeks’ gestational Age Not receiving immunoprophylaxis. Am J Perinatol. 2016. doi:10.​1055/​s-0036-1584147.PubMed
2.
Regnier SA, Huels J. Association between respiratory syncytial virus hospitalizations in infants and respiratory sequelae: systematic review and meta-analysis. Pediatr Infect Dis J. 2013;32:820–6.PubMed
3.
Roggeri DP, Roggeri A, Rossi E, Cataudella S, Martini N. Impact of hospitalizations for bronchiolitis in preterm infants on long-term health care costs in Italy: a retrospective case–control study. ClinEcon Outcome Res. 2016;8:407–12.CrossRef
4.
Committee on infectious diseases and bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;34:e620–38.CrossRef
5.
Bollani L, Baraldi E, Chirico G, Dotta A, Lanari M, Del Vecchio A, et al. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). It J Ped. 2015;41:97.CrossRef
Metadata
Title
Indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wGA group: is there still room for debating?
Authors
Gianvincenzo Zuccotti
Valentina Fabiano
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Italian Journal of Pediatrics / Issue 1/2017
Electronic ISSN: 1824-7288
DOI
https://doi.org/10.1186/s13052-017-0341-4

Other articles of this Issue 1/2017

Italian Journal of Pediatrics 1/2017 Go to the issue

Research

Long-term treatment with low-dose medicine in chronic childhood eczema: a double-blind two-stage randomized control trial

Research

The impact of an educational program on recognition, treatment and report of child abuse

Research

Pattern of drug use among preterm neonates: results from an Italian neonatal intensive care unit

Research

Childhood diarrheal morbidity and sanitation predictors in a nomadic community

Commentary

Novel insight into Chronic Inflammatory Demyelinating Polineuropathy in APECED syndrome: molecular mechanisms and clinical implications in children

Research

Efficacy of a mixture of probiotic agents as complementary therapy for chronic functional constipation in childhood